Therapy Detail

Therapy Name Celecoxib
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Celecoxib Celebra Celebra (celecoxib) is a COX-2 inhibitor FDA approved as an anti-inflammatory agent and for colorectal polyp reduction ( Celebra (celecoxib) also promotes apoptosis of tumor cells (PMID: 17909047).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown urinary bladder cancer not applicable Celecoxib Preclinical - Cell culture Actionable In a preclinical study, Celebra (celecoxib) treatment resulted in decreased cell viability in multiple human bladder cancer cell lines in culture (PMID: 27406983). 27406983
APC inact mut colorectal cancer sensitive Celecoxib Preclinical Actionable In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047). 17909047
Clinical Trial Phase Therapies Title Recruitment Status
NCT01729923 Phase II Capecitabine Celecoxib A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer Terminated
NCT01356290 Phase II Thalidomide Fenofibrate Etoposide Bevacizumab Celecoxib Cyclophosphamide + Cytarabine Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT) Recruiting
NCT02030964 Phase I Cyclophosphamide + Topotecan Celecoxib N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Active, not recruiting